, moving into and out of the bloodstream to engage bone marrow niches in sequential steps of homing, engraftment and retention [3] [4] [5] .
Here we show that HSPC engraftment of bone marrow in fetal development is dependent on the guanine-nucleotide-binding protein stimulatory a subunit (Ga s ). HSPCs from adult mice deficient in Ga s (Ga s
2/2
) differentiate and undergo chemotaxis, but also do not home to or engraft in the bone marrow in adult mice and demonstrate a marked inability to engage the marrow microvasculature. If deleted after engraftment, Ga s deficiency did not lead to lack of retention in the marrow, rather cytokine-induced mobilization into the blood was impaired. Testing whether activation of Ga s affects HSPCs, pharmacological activators enhanced homing and engraftment in vivo. Ga s governs specific aspects of HSPC localization under physiological conditions in vivo and may be pharmacologically targeted to improve transplantation efficiency.
Ga s is essential for normal development, with gene-deficient embryos showing fatal defects before day E10. 5 (ref. 6) . To overcome this limitation, chimaeric mice were generated by blastocyst injection of Ga s 2/2 embryonic stem cells 7 into a blastocyst transgenic for b-galactosidase (b-gal), enabling resultant embryos to be assessed for tissue chimaerism using in situ hybridization against neo in the targeting vector to score for Ga s 2/2 (knockout) cells and histochemical staining for b-gal to score for Ga s 1/1 (wild-type) cells (Fig. 1a) . On examining E17.5 embryos by in situ hybridization, chimaerism could be readily detected. Limb sections revealed neo-expressing Ga s 2/2 cell involvement in skin, muscle, bone and cartilage, but without evidence of contribution to bone marrow (Fig. 1b) . In contrast, as a positive control for the in situ hybridization, we examined limb sections from mice chimaeric for an unrelated knockout and could readily detect bone-marrow chimaerism ( Supplementary Fig. 1 Fig. 2 ). Therefore, the bone marrow appeared distinctive in its lack of contribution from Ga s ; Fig. 1d ) and no difference in colony-forming unit-culture (CFU-C) content between Ga s 1/1 and Ga s 2/2 chimaeric mononuclear cells (MNCs; Supplementary Fig. 3 ). Therefore, HSPCs form and have intact haematopoietic potential in the fetal liver even in the absence of Ga s , but without Ga s , there is a failure to engraft bone marrow by E17. Supplementary Fig. 4) . Analysis of the number of HSPCs in the bone-marrow MNCs, phenotypically defined as Lin , was also identical between the Mx1-Cre wild-type and Mx1-Cre knockout animals (wild type, 0.031 6 0.012%; knockout, 0.038 6 0.002%; P 5 0.545). Cells from the Mx1-Cre wild-type animals were able to engraft the bone marrow efficiently, whereas bone-marrow MNCs from the Mx1-Cre knockout mice were essentially absent from the bone marrow at early (4 weeks) and late (16 weeks) time points after transplantation (Fig. 2a) . Furthermore, when animals were transplanted with bone marrow cells from Mx1-Cre knockout mice in the absence of competing wild-type cells, spleen engraftment was significantly reduced as assessed by day 8 colony-forming unit-spleen (CFU-S 8 ) number ( Supplementary Fig. 5 ), and all animals died within 2 weeks, indicating a failure of extramedullary engraftment. Ga s is therefore required for HSPC engraftment in adult as well as in embryonic settings.
A failure to engraft successfully may reflect multiple abnormalities, which we sequentially examined. As others had previously found that pharmacological modifiers of the adenylyl cyclase pathways influenced myeloid differentiation in vitro 8, 9 , bone-marrow MNCs were obtained from Mx1-Cre wild-type and knockout mice and progenitor cell activity was analysed using the CFU-C assay. No significant differences were observed between the genotypes in colony number (Fig. 2b) , morphology or size. Similarly, analysis of the more primitive cell fraction using the long-term culture initiating cell (LTC-IC) assay demonstrated no significant differences between the wild-type and knockout cells (Fig. 2c) . Taken together, these data demonstrate that deletion of the Ga s gene does not alter the differentiation potential of primitive bone-marrow MNCs in vitro.
Migratory capacity was next assessed using the primitive Lin Fig. 6a ). In addition, there was no significant change in the chemotaxis of the more mature LKS 2 subset of cells ( Supplementary Fig. 6b ) or lymph node lymphocytes to SDF-1a, (data not shown) indicating that there was no generalized impairment of in vitro cell motility related to the Ga s defect.
Primitive cells isolated from bone-marrow MNCs of Mx1-Cre wild-type or knockout mice were then evaluated for in vivo capacity to home to the bone-marrow environment. Fluorescently labelled LKS 1 cells were injected into the peripheral circulation of mice and the numbers of cells present in the bone marrow and spleen were measured using flow cytometry at 6 h after injection. Deletion of Ga s in LKS 1 bone-marrow MNCs resulted in a marked impairment in their ability to home to both the bone marrow and spleen (Fig. 2d) . To examine whether this was specific to primitive cell homing to the bone marrow, or a more general defect, we examined the ability of the more mature LKS 2 and lymph node lymphocytes to home to haematopoietic organs. Whereas LKS 2 cells demonstrated a similar impairment as LKS 1 cells ( Supplementary Fig. 7a ), no defect in Ga s 2/2 lymphocytes (genotype confirmed by PCR) homing to lymph node, bone marrow or spleen was observed (Supplementary Fig. 7b ). These data argue against a generalized defect in cell homing associated with a deficiency of Ga s and identify a specific bone-marrow homing defect of primitive haematopoietic cells. To assess the specific homing defect of primitive Ga s 2/2 cells, we visualized HSPC homing in the calvarial bone-marrow endothelium using intravital confocal/two-photon videomicroscopy 12 . We found that Ga s 2/2
LKS
1 cells were defective in their interaction with the bone-marrow endothelium with significantly fewer cells observed rolling on the endothelial cells, whereas the number of cells retained in the circulation was significantly increased (Fig. 2e and Supplementary Movies 1 and 2). Therefore, Ga s is critical for the engagement of the bonemarrow vasculature by primitive haematopoietic cells, thereby enabling subsequent steps in stem-cell engraftment.
Deletion of the Ga s subunit resulted in significant reductions in the ability of primitive cells to establish haematopoiesis in the bonemarrow environment. Therefore, we examined whether the same deletion had any effects once engraftment of the cells in the bone marrow had been achieved. To study this, bone-marrow MNCs from Mx1-Cre wild-type or Mx1-Cre knockout mice were transplanted into wild-type mice. Eight weeks after transplantation, the mice were treated with polyI:C to induce gene deletion (Fig. 3a) . Longitudinal analysis demonstrated no significant differences between mice with Mx1-Cre wild-type or knockout cells in terms of peripheral blood complete blood count (CBC), bone-marrow CFU-C frequency ( Supplementary Fig. 8a-c) or HSPC frequency as assessed by immunophenotype (Fig. 3b) . Specific analysis of HSPC cell cycling status or number of apoptotic cells also indicated that there were no differences between the two different cell genotypes ( Supplementary Fig. 9a, b) . Furthermore, there was no evidence of HSPC enriched cell movement from the bone marrow to the peripheral blood by immunophenotypic analysis to indicate a retention defect. Rather, we did observe a striking defect in the ability of the Mx1-Cre knockout cells to be mobilized using granulocyte colony-stimulating factor (G-CSF; Fig. 3c ). These data demonstrate that Ga s signalling is not required for HSPC retention in the marrow, but under conditions of stress, mimicked here by G-CSF stimulation, trafficking out of the marrow space is impaired.
Genetic alteration of Ga s signalling demonstrated a central role in bone marrow homing of HSPCs. However, to determine if these findings might be relevant for medicine, we tested whether pharmacological modifiers of Ga s signalling could alter stem-cell function in vivo. We treated bone-marrow MNCs from wild-type C57BL/6 mice with cholera toxin, a compound known to constitutively activate Ga s by preventing GTP hydrolysis from the ADP-ribose-Ga s -GTP complex. Using a simple ex vivo exposure of cells for 1 h, we observed increased intracellular cAMP concentrations within haematopoietic cells by enzyme-linked immunosorbent assay (ELISA; data not shown). This resulted in an enhancement in the ability of treated cells to both home and engraft in the bone marrow, with approximately twofold increased engraftment at 16 weeks (Fig. 4a,  b) . To test whether the enhancement by cholera toxin was due to a nonspecific action of the compound, homing of Ga s 2/2 cells treated with cholera toxin was assessed; however, no improvement in the homing defect was observed (Supplementary Fig. 10 ). Because stimulation of Ga s -coupled receptors has also been noted to increase proliferation of HSPCs in developing zebrafish 13 , we tested whether murine LKS 1 cells treated with cholera toxin demonstrated increased cell cycling after transplantation. Cell cycle evaluation of labelled cells 2 days after injection into lethally irradiated hosts did not detect any difference between untreated and cholera-toxin-treated cells ( Supplementary Fig. 11 ). Therefore, cholera toxin acting at least in part through the Ga s -coupled pathway augments the homing of the cells and engraftment in the bone marrow. This effect on engraftment was durable and without distortion of mature cell subsets, indicating that the cholera-toxin-induced improvement in HSPC engagement of the niche did not compromise cellular function.
Elucidating the mechanisms by which HSPCs home to the bonemarrow environment has biological and medical implications that have made it an area of intense investigation. A number of molecules have been implicated; often they were studied because of their effects on other haematopoietic populations such as lymphocytes. Here we show that Ga s has a key role in the specific homing of HSPCs to the bone marrow, in a manner not shared by lymphocytes.
The inability of stem cells to migrate to the bone marrow in development strongly resembles the phenotype observed with the deletion of CXCR4 or SDF-1a (refs 14, 15) . This, coupled with an impairment in SDF-1a-responsive migration at specific concentrations in vitro, suggests that CXCR4 may be using Ga s as its predominant signalling pathway in that cell type. The data presented here do not rule out this possibility for fetal haematopoiesis. However, two important distinctions between the Ga s and CXCR4 null phenotypes exist for stem-cell function in adult animals. First, pharmacological interruption of CXCR4 signalling results in prompt mobilization of stem cells into the circulation 16 . Genetic disruption of Ga s resulted in no such change in location. Indeed, G-CSF-induced mobilization of cells from the bone marrow was impaired in the absence of Ga s , indicating that egress from the marrow may be diminished. Therefore, whereas CXCR4 is a key component of HSPC retention in the bone marrow 17 , it is not exerting its effect through Ga s . Second, CXCR4 null cells engraft in the bone marrow, whereas Ga s null cells do not 18 . It is therefore unlikely that the role of Ga s is simply downstream of CXCR4 as this molecule is dispensable for HSPC engraftment in the transplant setting.
Our results demonstrate that Ga s is critical at the HSPC homing stage, enabling engagement of the niche; however, continued Ga s signalling is not required to retain the cells there. There is then a meaningful molecular distinction between the homing, engraftment and retention processes. It could be hypothesized that the deficiency in the ability of the Ga s 2/2 cells to home to the bone marrow could lead to a depletion of the HSPCs in the marrow space and an accumulation in the blood. However, the decreased egress from the marrow may balance the decreased ingress. Alternatively, there may be compensatory changes in resident cells that mask changes in the population.
Another unknown from these studies is the potential upstream receptor using this pathway. The candidates are numerous and may include adrenergic and prostaglandin receptors. The report of prostaglandin E 2 (PGE 2 ) serving as a means of enhancing stem cell transplantation in mice 13 indicates that this is probably at least one receptor capable of activating the pathway. Whether PGE 2 mediates an effect physiologically in mammals could not be discerned from the data of ref. 13 ; however, our data indicate that the downstream pathway is critical for physiological processes in development.
The localization of stem cells after transplantation is a critical determinant of success of that clinical procedure. Currently, massive numbers of stem cells are required in clinical transplantation in part due to the limited efficiency of homing and engraftment. This is particularly problematic in umbilical cord blood transplantation where the number of stem cells is limited. This problem is being approached by dual unit transplantation, an expensive undertaking that indicates how a modest (twofold) increase in stem cells can profoundly affect clinical outcomes. Alternatives to the use of multiple unit infusions might be to increase the homing efficiency of the cells, increase the nurturing capacity of the niche or increase the number of cells by ex vivo expansion. Each approach has potential and with new information about the means of affecting each parameter, the possibility of translation to clinical trial. Transient exposure to agents stimulating Ga s is one such candidate approach. or Ga s fl/fl Mx1-Cre 1 mice were transplanted into wild-type mice. Eight weeks after transplantation, the mice were treated with polyI:C to induce deletion of the gene. Peripheral blood and bone-marrow MNCs were then evaluated at various time points after deletion. Cholera toxin treatment. Bone marrow MNCs from wild-type C57BL/6 mice were treated with cholera toxin (10 mg ml
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) for 1 h ex vivo. Treated cells were then used in in vivo homing and engraftment studies. 
